TNFSF11 and osteoporosis: After treatment with losartan, PD123319, and CGP42112A, RANKL expression was significantly decreased, OPG expression was slightly increased, and RANKL/OPG was significantly decreased (Figure 5A, C), which further suggests that RANKL-mediated osteoclast activity plays an important role in the development of osteoporosis.